Back to table of contents Next article Clinical & ResearchFull AccessCalls to Poison Centers Involving Psilocybin Rising in YouthTerri D'ArrigoTerri D'ArrigoPublished Online:10 May 2024https://doi.org/10.1176/appi.pn.2024.06.6.2AbstractDecriminalization, legalization of psilocybin likely play roles in both increased exposure and poisoning.Getty Images/iStock...
Background. Psychedelic drug policy is beginning to change, both in the U.S. and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for therapeutic efficacy...
Background. Psychedelic drug policy is beginning to change, both in the U.S. and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for therapeutic efficacy...
ObjectivesThe Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy tha...
A National Institute on Drug Abuse (NIDA)-funded study published in the journal Drug and Alcohol Dependence titled “National and Regional Trends in Seizures of Shrooms (Psilocybin) in the United States, 2017-2022” reported a significant increase in law enforcement seizures of psilocybin mushrooms, also known as “magic mushrooms” or “shrooms,” in the United S...
The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sampl...
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal po...
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA ...
AbstractBackground Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as "magic mushrooms." Existing literature demonstrates beneficial neurologic effects in treatment-resistant depression, cancer-associated depression and anxiety, and substance use. The evidence base for psilocybin use is on the ...
ABSTRACTBackground: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especial...
ABSTRACT Background: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especia...
This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special Issue "Psychedelics: New Doors, Altered Perceptions". Remarkable advances have been made in basic and clinical research on psychedelics in the five years since 2018. It is partly based on the seminar ...
This article presents an exploration of naturally occurring Class-A magic mushroom markets in the UK. It aims to challenge some of the mainstream narratives about drug markets and to identify features of this specific market, which will extend our understanding of how illegal drug markets operate and are structured more generally. The research presented comp...
The U.S. National Institutes of Health (NIH) convened a seminal first ever psychedelic drug substance-focused speaker series, from April 22 to June 10, 2021, titled the "NIH Psilocybin Research Speaker Series." This speaker series provided evidence-based scientific information to the public and the scientific community. Its aims were to assess the current st...
Background Recent survey data indicate that some people report long-term improvement in color vision deficiency (CVD), also known as color blindness, following use of psychedelics such as lysergic acid diethylamide (LSD) and psilocybin. However, there are no objective data reported in the medical literature quantifying the degree or duration of CVD improveme...
Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the difficulty of ensuring adequate blinding, the relative overrepresentation in studies of participants who have previously used psychedelics, and the importance of personal experience with psychedelics for those who ...
After decades of prohibition, psychedelics are generating intense public and private interest. Scientists are researching the therapeutic properties of these substances, and mounting evidence supports their ability to treat a variety of mental health conditions. Meanwhile, dozens of cities and states are proposing or enacting psychedelics legislation to prom...
